TECHNICAL NOTES

Wagg&Purr®

Meloxicam Dog Oral Suspension

Active Constituents

Meloxicam 1.5 mg/mL

Actions

Meloxicam is a non-steroidal anti-inflammatory compound of the oxicam group, which acts by inhibition of prostaglandin synthesis. Meloxicam exerts anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It inhibits leukocyte infiltration into the inflamed tissue and prevents bone and cartilage destruction. To a minor extent, it also inhibits collagen-induced thrombocyte aggregation.

Indications

Wagg & Purr® Meloxicam Dog Oral Suspension is a non-steroidal anti-inflammatory drug (NSAID) for use in dogs. It is indicated for the alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders such as disco-spondylosis, arthropathy and soft tissue injuries.

Contraindications

This product is contraindicated for use in pregnant or lactating bitches.

The use of the product is contraindicated in animals suffering from cardiac, hepatic or clinical renal disease.

This product is also contraindicated where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a haemorrhagic disorder or individual hypersensitivity to the product.

Wagg & Purr® Meloxicam Dog Oral Suspension should not be administered concurrently with steroidal or other non-steroidal anti-inflammatory drugs, amino-glycoside antibiotics or anti-coagulant agents.

Pre-treatment with anti-inflammatory drugs may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement with Wagg & Purr® Meloxicam Dog Oral Suspension. The treatment-free period, however, should take into account the pharmacokinetic properties of the drugs used previously.

Precautions

As for all NSAIDs, use in any animals less than 6 weeks of age or in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided, careful clinical management may be required.

Side Effects

Typical adverse reactions of NSAIDs may occur (particularly within the first week of treatment). These may include loss of appetite, vomiting, diarrhoea, faecal occult blood and lethargy. In very rare cases, haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These side effects are in most cases transient and disappear following termination of treatment but in very rare cases may be serious. If side effects are persistent or of severity, treatment should be discontinued, and the advice of the veterinarian should be sought.

In case of overdosing, symptomatic treatment should be initiated.

Dosage & Administration

SHAKE WELL BEFORE USE.

Wagg & Purr® Meloxicam Dog Oral Suspension should be administered mixed with food. On the first day of treatment a single dose of 0.2 mg/kg bodyweight should be given. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg/kg bodyweight.

Particular care should be given with regard to the accuracy of dosing.

Wagg & Purr® Meloxicam Dog Oral Suspension is administered by use of a graduated measuring syringe (0.5 mL increments) which is provided in the package. The syringe fits onto the bottle and has a kg-bodyweight scale designed for the maintenance dose (i.e. 0.1 mg/kg bodyweight). Thus, twice the volume should be administered on the first day as the initial dose. The following dosing table indicates what volume to administer depending on the weight of the dog:

Bodyweight	Maintenance Dose	Bodyweight	Maintenance Dose
7.5 kg	0.5 mL	37.5 kg	2.5 mL
15 kg	1 mL	45 kg	3 mL
22.5 kg	1.5 mL	52.5 kg	3.5 mL
30 kg	2 mL	60 kg	4 mL

Initial Dose:

0.2 mg/kg bodyweight

2 maintenance dosage volumes

Maintenance Dose:

0.1 mg/kg bodyweight

1 maintenance dosage volume

For longer term treatment, once clinical response has been observed (after ≥ 4 days), the dose of Wagg & Purr® Meloxicam Dog Oral Suspension can be adjusted to the lowest effective individual dose, reflecting that the degree of pain and inflammation associated with chronic musculoskeletal disorders may vary over time. Should longer term treatment be contemplated, the prescribing veterinarian should observe current best practice including, but not limited to, regular monitoring of relevant clinical and biochemical parameters. If no improvement is noticeable after 10 days of treatment, please consult a veterinary surgeon.

Safety

Harmful if swallowed. May irritate the eyes and skin. Avoid contact with eyes and skin. When using the product wear disposable gloves. Wash hands after use.

Safety Data Sheet

For Safety Data Sheet see www.avet.health

First Aid

If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 13 11 26.

Presentation

Carton containing plastic bottle and syringe; 15 mL, 42 mL, 100 mL, 200 mL.

Disposal

Dispose of used packaging by wrapping in paper and putting in garbage.

Storage

Store below 25°C (air conditioning). Do not freeze.

Poisons Schedule

S4

Registration Numbers

APVMA Approval Number: 63653